Thus, this study aims to analyze the role of ALDH1A2, ALDH3A1, and ALDH16A1 genetic variability in MDS and AML development and progression, in order to identify new potential risk factors and/or prognostic markers. This evidence concerns the gene ALDH3A1 and myelodysplastic syndrome.